I don't think you can bring remuneration down for FY18:
- as the performance rights for FY17 vest around now and in June 2018, and should appear in FY18 accounts
- unless both non executive directors are replaced, the management-friendly Board will grant management pay rises and bonuses, irrespective of total returns to shareholders (which since the reverse takeover has been negative)
- even if the remuneration is voted down in November 2017, the Board can still go ahead with remuneration, and then hire a remuneration consultant (the same ones they are using now, of course) to say it is consistent with (appalling) market practices
- the restructuring costs for removing management are probably onerous, and then there is a need to find replacements.
The rest is probably doable, except reducing interest costs to that level.
- Forums
- ASX - By Stock
- LAW
- Ann: Investor Presentation
Ann: Investor Presentation, page-25
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add LAW (ASX) to my watchlist
(20min delay)
|
|||||
Last
0.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $319.3K |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
LAW (ASX) Chart |
Day chart unavailable
The Watchlist
LGP
LITTLE GREEN PHARMA LTD
Paul Long, Chief Executive Officer
Paul Long
Chief Executive Officer
SPONSORED BY The Market Online